44-6-1 (ATCC® CRL-2491™)

Organism: Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)  /  Cell Type: hybridoma:lymphoblast B lymphocyte; somatic cell hybri

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Organism Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma)
Cell Type hybridoma:lymphoblast B lymphocyte; somatic cell hybri
Product Format frozen
Morphology lymphoblast
Culture Properties suspension
Biosafety Level 1
Applications
Animals were immunized against 1D2, a BALB/cJ mouse IgG1 monoclonal antibody specific for ricin A chain.
The 44-6-1 (ATCC CRL-2491) and 44-26-2 (ATCC CRL-2492) cell lines produce antibodies that bind specifically to an idiotypic determinant on 1D2 anti-ricin monoclonal antibody.
Storage Conditions liquid nitrogen vapor phase
Derivation
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
Genes Expressed
immunoglobulin; monoclonal antibody; against an idiotypic determinant on 1D2 (anti-ricin A chain monoclonal antibody)
Comments
Animals were immunized against 1D2, a BALB/cJ mouse IgG1 monoclonal antibody specific for ricin A chain.
Spleen cells were fused with P3X63Ag8.653 mouse myeloma cells.
The 44-6-1 (ATCC CRL-2491) and 44-26-2 (ATCC CRL-2492) cell lines produce antibodies that bind specifically to an idiotypic determinant on 1D2 anti-ricin monoclonal antibody.
The 44-6-1 and 44-26-2 monoclonals conjugated to keyhole limpet hemocyanin (KLH) have been shown to induce anti-ricin antibodies in mice.
Complete Growth Medium Iscove's modified Dulbecco's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate, 85%; fetal bovine serum, 15%
Subculturing
Protocol: Cultures can be maintained by addition of fresh medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10(5) viable cells/ml. Do not allow the cell concentration to exceed 6 X 10(5) viable cells/ml.
Interval: Maintain cultures at a cell concentration between 5 X 10(4) and 6 X 10(5) cells/ml.
Medium Renewal: Add fresh medium every 2 to 3 days (depending on cell density)
Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 X 10 exp5 viable cells/ml.
Maintain cell density between 5 X 10 exp4 and 6 X 10 exp5 viable cells/ml.
Cryopreservation
Freeze medium: Complete growth medium supplemented with 5% (v/v) DMSO
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
Temperature: 37.0°C
Isotype mouse IgG2b
Name of Depositor DG Sieckmann
Year of Origin 1995
References

Sieckmann DG, et al. Development of an anti-idiotypic vaccine for ricin. J. Allergy Clin. Immunol. 99: S286, 1997.

Permits Notice: Necessary Permits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Product Sheet
Product Sheet
Certificate of Analysis
Certificate of Analysis
MSDS
MSDS
Restrictions This cell line was deposited at the ATCC by Donna G. Sieckmann, Naval Medical Research Center. The line is distributed for academic research purposes only. The Naval Medical Research Center releases the line subject to the following: 1.) The line or its products must not be distributed to third parties. Commercial interests are the exclusive property of the Naval Medical Research Center. 2.) Any proposed commercial use of the cell line including any use by a for-profit entity must first be negotiated with the Commanding Officer, Naval Medical Research Center, 503 Robert Grant Avenue, Silver Spring, MD 20910-7500.
References

Sieckmann DG, et al. Development of an anti-idiotypic vaccine for ricin. J. Allergy Clin. Immunol. 99: S286, 1997.